Clinical Blogs

A Softer View of Drug Addiction

by Michael Nguyen, PharmD, CPh
Director of Clinical Pharmacy

Michael Nguyen

In a first report of its kind, the Office of the Surgeon General is providing a framework for addressing America’s crippling alcohol and drug addiction problem. The 428-page report, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, contains a chapter on neurobiology, which compares alcohol and substance addiction to other …

How Will the 21st Century Cures Act Impact Workers’ Comp?

by Devin Motley
Regulatory Counsel

On December 13, 2016, President Obama signed H.R.34, known as the 21st Century Cures Act, into law. Advertised as a victory for bi-partisan cooperation in Congress, the legislation aims to tackle critical health issues facing American society including combating the opioid epidemic, funding cancer research, addressing mental health care, and modifying what approval is required …

Proposed Legislation in Pennsylvania: Senate Bill 1349

by Devin Motley
Regulatory Counsel

Pennsylvania Senate Bill 1349 introduced 10/12/16 would make Pennsylvania the latest state to limit opioid prescriptions. There are three key points to the legislation: Seven-Day Limitation As a general rule, medical professionals “may not prescribe to an individual more than a seven-day supply of a controlled substance containing an opioid.” If a prescriber in their …

It’s a Partnership with our Clients – Patient Advocacy is our Top Priority

by Devin Motley
Regulatory Counsel

The United States Department of Labor released a study October 5, 2016 entitled “Does the workers’ compensation system fulfill its obligations to injured workers?” A full copy of the report can be found here. The release of the report was accompanied by a webinar co-sponsored by the National Academy of Social Insurance, and included speakers …

FDA Black Box Warnings for Combined Opioid and Benzodiazepine Use

by Michael Nguyen, PharmD, CPh, Director of Clinical Services
Andi Moore, PharmD

Michael Nguyen

After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced on August 31, 2016, that class-wide changes to drug labeling, including patient information, was being required for the opioid and benzodiazepine therapeutic classes because of serious risks associated with using medications from these two classes at the same time. …